Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Known title: 10% OwnerCIK: 0001615258
Associated companies
Transaction History
| NATR | ▼ Sell | Open Market | 2,854,607 | $32.7M | 6/27/2025 | View on chart |
| NATR | ▼ Sell | Open Market | 2,300 | $30K | 10/15/2024 | View on chart |
| NATR | ▼ Sell | Open Market | 1,300 | $17K | 10/14/2024 | View on chart |
| NATR | ▼ Sell | Open Market | 1,580 | $21K | 10/11/2024 | View on chart |
| NATR | ▼ Sell | Open Market | 3,000 | $40K | 10/10/2024 | View on chart |
| NATR | ▼ Sell | Open Market | 1,816 | $24K | 10/9/2024 | View on chart |
| NATR | ▼ Sell | Open Market | 1,800 | $24K | 10/8/2024 | View on chart |
| NATR | ▼ Sell | Open Market | 1,399 | $19K | 10/1/2024 | View on chart |
| NATR | ▼ Sell | Other | 2,968 | $0 | 9/6/2024 | View on chart |
| NATR | ▼ Sell | Other | 25,000 | $218K | 1/21/2022 | View on chart |
| NATR | ▼ Sell | Other | 9,558 | $0 | 1/7/2022 | View on chart |
| NATR | ▼ Sell | Other | 711 | $0 | 4/12/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Nature's Sunshine Q2 Earnings Reviewed Against Peers
A recent analysis compared Nature's Sunshine's second-quarter results with other personal care companies. This review helps investors understand how the stock performed relative to its sector during that period. The company currently trades with a trailing P/E ratio of 13.3, while analysts maintain an average price target of $30.50.
Nature's Sunshine Q2 Earnings Reviewed Against Peers. A recent analysis compared Nature's Sunshine's second-quarter results with other personal care companies. This review helps investors understand how the stock performed relative to its sector during that period. The company currently trades with a trailing P/E ratio of 13.3, while analysts maintain an average price target of $30.50.